Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Autonomous Technologies, Inc. (ATI), developer and manufacturer of Pulsante, a microstimulator for the treatment of severe headaches, today announced the closing of its D-Series funding round for an additional $5. HBM Healthcare Investments LTD 5M This brings the ATI round D funding to a total of $43. 2M 2M The round was led by Edmond de Rothschild Investment Partners (EdRIP), a Paris-based venture capital firm, syndicated with Forbion Capital Partners, from Naarden, Netherlands. Existing investors Kleiner Perkins Caufield and Byers, InterWest Partners, Aberdare Ventures, Novatis Venture Funds and Cleveland Clinic have also invested.

ATI has started commercializing the Pulsante microstimulator in Europe and has also established Autonomic Technologies Europe GmbH, a wholly owned subsidiary in Germany, to further expand European commercialisation. Pulsante GSP Microstimulator System (also known as Autonomous Technologies, Inc. (ATI) Neurostimulation system) is part of an IDE study in the US for the treatment of chronic cluster headache. The company will use the proceeds from the financing to finance the ongoing IDE study in the USA.

‘Autonomic Technologies’ strong clinical data, a unique product portfolio and an excellent commercial team in Europe make this neuromodulation investment a perfect fit for HBM,’ said Dr. Alexander Asam Investment Advisor to HBM Partners AG

‘Financing round D above target is a testament to the strong performance of ATI and enables accelerated expansion to international markets with Pulsante, ATI’s novel microstimulation therapy that gives new hope to patients suffering from debilitating effects of severe headaches,’ said Karl Schweitzer, Chief Commercial Officer of Autonomic Technologies.

About Autonomous Technologies

Autonomous Technologies, Inc. (ATI) is a medical device company headquartered in the San Francisco Bay Area, with offices in Germany and Switzerland, dedicated to the development and commercialization of innovative therapy for the treatment of autonomic disorders, particularly severe headaches. The initial product of the company, the Pulsante microstimulator, is CE-marked in Europe for the treatment of cluster headache. Device (also known as Autonomous Technologies, Inc. (ATI) Neurostimulation system) is also part of an IDE study in the US for the treatment of chronic cluster headache. For more information, please visit: Pulsant UA or www ATIP-SPG Come on,

Information about HBM Healthcare Investments Ltd.

HBM Partners Ltd is a global leader in healthcare-focused investment with approximately USD 1 billion under management. HBM focuses on the stage of development, growth and buy-out financing of private companies as well as investment in public companies. HBM Partners Ltd advises HBM Healthcare Investments AG, HBM BioCapital and other specialized private equity and public equity funds. HBM has an additional team of experienced professionals to source, analyze, execute and exit investments in the pharmaceutical/biotech, medical devices and diagnostics industries. HBM Partners Ltd has been an active contributor to value creation in its portfolio companies, generating more than 40 business sales and IPOs since its inception.

Please note that this piece of work originally appeared in English at As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at

Leave a Reply

Your email address will not be published. Required fields are marked *